Post by Biocartis

47,700 followers

๐—๐—ข๐—œ๐—ก ๐—ข๐—จ๐—ฅ ๐—™๐—ฅ๐—˜๐—˜ ๐—ช๐—˜๐—•๐—œ๐—ก๐—”๐—ฅ: ๐—–๐—ฅ๐—– ๐—ง๐—ฒ๐˜€๐˜๐—ถ๐—ป๐—ด ๐—ถ๐—ป ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ: ๐—ช๐—ต๐—ฎ๐˜'๐˜€ ๐—ก๐—ฒ๐˜„, ๐—ช๐—ต๐—ฎ๐˜'๐˜€ ๐—ก๐—ฒ๐˜…๐˜? ๐—”๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐—ถ๐˜€๐˜'๐˜€ ๐—ฃ๐—ฒ๐—ฟ๐˜€๐—ฝ๐—ฒ๐—ฐ๐˜๐—ถ๐˜ƒ๐—ฒ ๐—ผ๐—ป ๐—•๐—ถ๐—ผ๐—บ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐—ฟ ๐—ง๐—ฒ๐˜€๐˜๐—ถ๐—ป๐—ด ๐Ÿ“… Thursday 25 June, 13:00 (CEST) ๐ŸŽค Professor Jenny Seligmann (Consultant Medical Oncologist, Leeds Teaching Hospitals NHS Trust & Professor of Gastrointestinal Oncology, University of Leeds) ๐Ÿ“ Online, registration required ๐—›๐—ถ๐—ด๐—ต๐—น๐—ถ๐—ด๐—ต๐˜๐˜€: - The key changes in ESMO mCRC guidelines - The role of dual IHC/molecular testing for immunotherapy eligibility - The emerging testing strategies in early-stage disease ๐Ÿ‘‰ ๐—ฆ๐—ฎ๐˜ƒ๐—ฒ ๐˜†๐—ผ๐˜‚๐—ฟ ๐˜€๐—ฝ๐—ผ๐˜ ๐—ป๐—ผ๐˜„: https://lnkd.in/eCACjXx3 Canโ€™t join live? By registering, you will get access to the recording afterwards. #Biocartis #Idylla #CRC #mCRC #Oncology #BiomarkerTesting #ESMO

Post content